RecruitingRecruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360 · Cullinan Therapeutics Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)
About this study
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Eligibility criteria
Inclusion Criteria:
* Diagnosis of SLE at least 24 weeks prior to Screening and meet 2019 EULAR / ACR Classification Criteria at screening.
* Presence of one or more of the following autoantibodies documented during screening or in the previous 12 months before screening: positive anti-nuclear antibody (ANA) test (≥1:80); anti dsDNA above the upper limit of normal (ULN); anti-Sm above the ULN.
* Active SLE disease, as demonstrated by a SLEDAI total score ≥6 at screening.
* Inadequate response to at least 2 of the following treatments: oral corticosteroid, antimalarials, conventional immunosuppressants, or biologics. At least one of the failed treatments should be an immunosuppressive or biologic standard-of care agent.
* If on corticosteroid and/or antimalarial, the dose must be stable prior to day 1.
* Laboratory parameters including the following:
* Absolute lymphocyte count (ALC) ≥0.5 x 109/L
* Peripheral B cell count ≥25 cells/µL
* Absolute neutrophil count (ANC) ≥1.0 x 109/L
* Hemoglobin ≥8 g/dL
* Platelet count ≥75 x 109/L.
* Estimated glomerular filtration rate (eGFR) (based on CKD-EPI formula) ≥30 mL/min/1.73m2
* Total bilirubin ≤1.5 × ULN, except patients with confirmed Gilbert's Syndrome
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN
* Part B only: For patients who were treated in Part A and did not experience dose-limiting toxicity (DLT) or discontinue CLN-978 treatment due to AEs are eligible for retreatment at a higher dose or longer schedule in Part B if they otherwise meet eligibility criteria and at least 90 days have passed since the last dose of CLN-978.
Exclusion Criteria:
* Active inflammatory disease other than SLE. Thyroiditis or secondary Sjogren's syndrome is allowed.
* Considered at high risk for thrombosis.
* Rapidly progressive glomerulonephritis, and/or urine protein/creatinine \>3 mg/mg (339 mg/mmol).
* Active severe neuropsychiatric/CNS manifestations of SLE.
* Evidence of hepatitis B, hepatitis C (HCV) infection, human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) infection.
* History of splenectomy.
* Prior treatment with the following:
* Cellular or gene therapy product directed at any target.
* Investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to Day 1.
* Any anti-CD19 or anti-CD20 therapy less than 3 months prior to Day 1.
* Non-biologic DMARD within 14 days prior to Day 1.
* Cyclophosphamide within 1 month or a biologic immunomodulating therapy during 2 months prior to Day 1.
* Live or attenuated vaccine within 28 days prior to screening or during screening.
* Active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including SARS-CoV-2 infection, within 14 days before Day 1.
* Active or latent tuberculosis (TB) evidenced by a positive or indeterminant Interferon Gamma Release Assay (IGRA), unless the patient has documented previous completion of TB treatment and no current clinical indication of TB.
* Any condition for which, in the opinion of the Investigator and/or Sponsor, would not be in the best interest of the patient to participate in the study or that could prevent, limit, or confound any protocol-defined assessment.
Study design
Enrollment target: 24 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-01-21
Estimated completion: 2027-12
Last updated: 2026-10-26
Interventions
Drug: CLN-978
Primary outcomes
- • Safety and tolerability (48 weeks)
Sponsor
Cullinan Therapeutics Inc. · industry
Contacts & investigators
ContactMeagan Sardinha · contact · ClinOps@cullinantx.com · +1 617 410 4650
All locations (24)
AARA Clinical ResearchRecruiting
Avondale, Arizona, United States
AARA Clinical ResearchRecruiting
Tucson, Arizona, United States
Omega Research GroupRecruiting
Orlando, Florida, United States
University of IowaRecruiting
Iowa City, Iowa, United States
Boston Children's HospitalRecruiting
Boston, Massachusetts, United States
NYU Grossman School of MedicineRecruiting
New York, New York, United States
Columbia University Medical CenterWithdrawn
New York, New York, United States
University of Rochester Medical CenterRecruiting
Rochester, New York, United States
Regional One HealthRecruiting
Memphis, Tennessee, United States
Stryde ResearchRecruiting
Plano, Texas, United States
Tranquil Clinical ResearchRecruiting
Webster, Texas, United States
Intermountain HealthRecruiting
Salt Lake City, Utah, United States
Royal Melbourne HospitalRecruiting
Parkville, Australia
Osteoporosis SolutionsRecruiting
Victoria Park, Australia
Multi profile Hospital for Active Treatment Sveta SofiaRecruiting
Sofia, Bulgaria
CHU de NantesRecruiting
Nantes, France
University Hospital Saint EtienneRecruiting
Saint-Priest-en-Jarez, France
Centre Hospitalier Universitaire de ToulouseRecruiting
Toulouse, France
ARENSIA Exploratory Medicine, LLCRecruiting
Tbilisi, Georgia
Klinikum der Ruprecht-Karls Universitaet HeidelbergRecruiting
Heidelberg, Baden-Wurttemberg, Germany
Timofei Moșneaga Republican Clinical HospitalWithdrawn
Chisinau, Moldova
ARENSIA Exploratory Medicine S.R.L.Recruiting
Bucharest, Romania
Arensia Exploratory MedicineRecruiting
Cluj-Napoca, Romania
Hospital Quironsalud Infanta LuisaRecruiting
Seville, Spain